on the evening of January 15, 2024, the domestic herpes zoster vaccine enterprise 100g biological (688276.SH) released its 2023 performance forecast.

according to the report, the company expects to achieve net profit attributable to shareholders of listed companies of 0.47 billion yuan to 0.53 billion yuan in 2023, an increase of 158.90 to 191.95 per cent compared with the same period last year (statutory disclosure data).

This performance growth rate is higher than the company's growth rate in the first three quarters of 2023. The latter's net profit attributable to shareholders of listed companies increased by 56.31 year-on-year.

Baike Biology said that the company expects to achieve operating income of 1.76 billion to 1.87 billion yuan in 2023, resulting in a year-on-year increase in net profit attributable to shareholders of listed companies.

This is mainly due to the sale of the herpes zoster vaccine.

in January 2023, 100 grams of biological herpes zoster vaccine was approved in the domestic market, becoming the first domestic listed herpes zoster vaccine. In April of that year, this live attenuated herpes zoster vaccine obtained the "Biological Products Batch Issuance Certificate" and started vaccination that month.

Baike biological said in the performance forecast that during the reporting period, the company's live attenuated herpes zoster vaccine was approved for listing, completed the access work of 30 provinces, autonomous regions and municipalities directly under the central government, and successively realized sales and vaccination, enriching the types of vaccines of the company. At the same time, the company took the opportunity of the listing of live attenuated herpes zoster vaccine as an opportunity to build a digital marketing model, actively broaden product promotion channels, further promote product export, and take multiple measures to enhance the company's product market competitiveness, helping the company's overall revenue scale and net profit It is expected to rise year-on-year.

Herpes zoster is an infectious skin disease caused by the reactivation of varicella-zoster virus that has long been latent in the posterior spinal ganglia or cranial ganglia. With the increase of age, the physiological metabolic function and immune function of the elderly gradually decline, and the risk of infectious diseases such as herpes zoster is significantly increased. Vaccination against herpes zoster is an effective measure to prevent herpes zoster. As China's aging population accelerates, the herpes zoster vaccine market is seen as promising in the future.

up to now, including 100 grams of live attenuated herpes zoster vaccine, a total of two herpes zoster vaccines have been approved for listing in the Chinese market, and the other is an imported vaccine, namely GlaxoSmithKline (GSK) herpes zoster recombinant vaccine. These two vaccines also form a differentiated competition, the technical route is different, from the protection, the import vaccine data is better. In terms of price, domestic vaccines are cheaper. In addition, domestic vaccines are aimed at a wider range of people, with vaccination targets for people aged 40 and above, while imported vaccines are aimed at people aged 50 and above.

From the current point of view, there is an increasingly fierce competition in the herpes zoster vaccine market.

in October 2023, in order to expand market sales, GSK chose to hand over the marketing, promotion, import and distribution of its herpes zoster recombinant vaccine in mainland China to Zhifei biology, a domestic vaccine company. According to the announcement issued by Zhifei Biology in the early stage, the agreement stipulates that the company's minimum annual purchase amount of herpes zoster vaccine in 2024, 2025 and 2026 is 3.44 billion yuan, 6.88 billion yuan and 10.32 billion yuan respectively.

at present, many vaccine enterprises are also developing new herpes zoster vaccines, including domestic enterprises such as kangsinuo, green bamboo biology, Shanghai institute of biological products, zhonghui yuantong, maikekang biology, ruike biology, jiachen xihai (Hangzhou) biotechnology co., ltd.